[go: up one dir, main page]

UY32037A - Daa-piridina - Google Patents

Daa-piridina

Info

Publication number
UY32037A
UY32037A UY0001032037A UY32037A UY32037A UY 32037 A UY32037 A UY 32037A UY 0001032037 A UY0001032037 A UY 0001032037A UY 32037 A UY32037 A UY 32037A UY 32037 A UY32037 A UY 32037A
Authority
UY
Uruguay
Prior art keywords
compounds
daa
pyridine
compositions
elements
Prior art date
Application number
UY0001032037A
Other languages
English (en)
Inventor
Lehmann Dr Lutz
Thiele Andrea
Heinrich Tobias
Vollmer Sonja
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of UY32037A publication Critical patent/UY32037A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Pulmonology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nuclear Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos nuevos adecuados para marcar o ya marcados con 18F, con métodos para preparar tales compuestos, con composiciones que comprenden dichos compuestos, con conjuntos de elementos que comprenden dichos compuestos, composiciones o conjunto de elementos en terapia y para diagnóstico por imágenes mediante tomografía de emisión de positrones (PET).
UY0001032037A 2008-08-06 2009-08-05 Daa-piridina UY32037A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08161903 2008-08-06

Publications (1)

Publication Number Publication Date
UY32037A true UY32037A (es) 2010-03-26

Family

ID=41198601

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032037A UY32037A (es) 2008-08-06 2009-08-05 Daa-piridina

Country Status (24)

Country Link
US (1) US20110200535A1 (es)
EP (1) EP2321279B1 (es)
JP (1) JP2011529929A (es)
KR (1) KR20110041559A (es)
CN (1) CN102112448B (es)
AR (1) AR073263A1 (es)
AU (1) AU2009278279B2 (es)
BR (1) BRPI0917099A2 (es)
CA (1) CA2733105A1 (es)
CL (1) CL2011000237A1 (es)
CO (1) CO6351715A2 (es)
CR (1) CR20110064A (es)
DO (1) DOP2011000046A (es)
EA (1) EA018650B1 (es)
EC (1) ECSP11010808A (es)
IL (1) IL210597A0 (es)
MX (1) MX2011001406A (es)
NZ (1) NZ590923A (es)
PE (1) PE20110226A1 (es)
SV (1) SV2011003830A (es)
TW (1) TW201010734A (es)
UY (1) UY32037A (es)
WO (2) WO2010015340A1 (es)
ZA (1) ZA201101700B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2114873E (pt) 2006-12-26 2013-05-06 Lantheus Medical Imaging Inc Ligandos para imagiologia de inervação cardíaca
WO2010015340A1 (en) * 2008-08-06 2010-02-11 Bayer Schering Pharma Aktiengesellschaft Daa-pyridine as peripheral benzodiazepine receptor ligand for diagnostic imaging and pharmaceutical treatment
GB0904715D0 (en) * 2009-03-19 2009-05-06 Ge Healthcare Ltd Aryloxyanilide derivataives
WO2011110488A1 (en) * 2010-03-09 2011-09-15 Bayer Pharma Aktiengesellschaft A novel pet imaging agent of amyloid plaques and its precursor
MX367382B (es) * 2010-05-11 2019-08-19 Lantheus Medical Imaging Inc Composiciones, metodos y sistemas para la sintesis y el uso de agentes trazadores.
CA2799381A1 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Male contraceptive compositions and methods of use
MX354217B (es) * 2010-05-14 2018-02-19 Dana Farber Cancer Inst Inc Composiciones y metodos para el tratamiento de leucemia.
PL2571503T3 (pl) 2010-05-14 2015-06-30 Dana Farber Cancer Inst Inc Kompozycje i sposoby leczenia nowotworu, choroby zapalnej i innych zaburzeń
CN104159890B (zh) 2011-09-09 2018-04-10 蓝瑟斯医学影像公司 用于合成和使用显像剂的组合物、方法和系统
MX2016001037A (es) 2013-07-25 2016-11-10 Dana Farber Cancer Inst Inc Inhibidores de factores de transcripción y usos.
MX379463B (es) 2013-11-08 2025-03-10 Dana Farber Cancer Inst Inc Terapia de combinación para el cáncer usando inhibidores de la proteína bromodominio y extra-terminal.
US10150756B2 (en) 2014-01-31 2018-12-11 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
EP3099693A4 (en) 2014-01-31 2017-08-16 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
JP2017506666A (ja) 2014-02-28 2017-03-09 テンシャ セラピューティクス，インコーポレイテッド 高インスリン血症に関連した症状の処置
RU2017104897A (ru) 2014-08-08 2018-09-10 Дана-Фарбер Кэнсер Инститьют, Инк. Производные диазепана и их применения
WO2016022970A1 (en) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Dihydropteridinone derivatives and uses thereof
EP3212654B1 (en) 2014-10-27 2020-04-08 Tensha Therapeutics, Inc. Bromodomain inhibitors
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
RU2018112953A (ru) 2015-09-11 2019-10-14 Дана-Фарбер Кэнсер Инститьют, Инк. Ацетамидтиенотриазолодиазепины и пути их применения
PE20181287A1 (es) 2015-09-11 2018-08-07 Dana Farber Cancer Inst Inc Ciano tienotriazolpirazinas y usos de las mismas
US10913752B2 (en) 2015-11-25 2021-02-09 Dana-Farber Cancer Institute, Inc. Bivalent bromodomain inhibitors and uses thereof
CN105541931B (zh) * 2016-01-07 2018-08-17 江西师范大学 一种氟代糖苷衍生物及其制备方法
US20200369675A1 (en) * 2017-12-01 2020-11-26 UCB Biopharma SRL Imaging Agents
CN111039853B (zh) * 2019-12-26 2023-02-14 安徽大学 一种可用于光声成像和光热治疗的铁配合物及其制备方法和用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU729000B2 (en) * 1997-08-04 2001-01-25 Nihon Nohyaku Co., Ltd. Aryloxyaniline derivatives
JP2000001476A (ja) * 1998-06-15 2000-01-07 Taisho Pharmaceut Co Ltd アリールオキシ含窒素アリールアミン誘導体
JP2004231647A (ja) * 2003-01-10 2004-08-19 Natl Inst Of Radiological Sciences フェニルオキシアニリン誘導体
US6870069B2 (en) * 2003-01-10 2005-03-22 National Institute Of Radiological Sciences Phenyloxyaniline derivatives
GB0329716D0 (en) * 2003-12-23 2004-01-28 Amersham Plc Radical trap
WO2007010534A2 (en) * 2005-07-19 2007-01-25 Spectrum Dynamics Llc Imaging protocols
GB0407952D0 (en) * 2004-04-08 2004-05-12 Amersham Plc Fluoridation method
DE102005055524B4 (de) * 2005-11-22 2013-02-07 BEGO Bremer Goldschlägerei Wilh. Herbst GmbH & Co. KG Verfahren, Vorrichtung und System zur Herstellung eines keramischen Formkörpers
US20080293969A1 (en) * 2005-11-22 2008-11-27 Ge Healthcare Limited 18F-Labeled Daa Analogues and Method of Labeling These Analogues as Positron Emission Tomography (Pet) Tracers For Imaging Peripheral Benzodiazepine Receptors
GB0525949D0 (en) * 2005-12-21 2006-02-01 Hammersmith Imanet Ltd Pet radiotracers
JP5916039B2 (ja) * 2006-06-21 2016-05-11 ジーイー・ヘルスケア・リミテッド 放射性医薬品製品
WO2010015340A1 (en) * 2008-08-06 2010-02-11 Bayer Schering Pharma Aktiengesellschaft Daa-pyridine as peripheral benzodiazepine receptor ligand for diagnostic imaging and pharmaceutical treatment

Also Published As

Publication number Publication date
ZA201101700B (en) 2014-08-27
DOP2011000046A (es) 2011-02-28
CN102112448A (zh) 2011-06-29
AU2009278279A1 (en) 2010-02-11
CL2011000237A1 (es) 2011-07-29
MX2011001406A (es) 2011-03-21
EA018650B1 (ru) 2013-09-30
AR073263A1 (es) 2010-10-28
US20110200535A1 (en) 2011-08-18
WO2010015387A1 (en) 2010-02-11
EP2321279B1 (en) 2014-07-02
TW201010734A (en) 2010-03-16
CN102112448B (zh) 2014-08-06
EP2321279A1 (en) 2011-05-18
CR20110064A (es) 2011-03-30
JP2011529929A (ja) 2011-12-15
IL210597A0 (en) 2011-03-31
CO6351715A2 (es) 2011-12-20
PE20110226A1 (es) 2011-04-01
EA201100301A1 (ru) 2011-12-30
SV2011003830A (es) 2011-05-20
CA2733105A1 (en) 2010-02-11
KR20110041559A (ko) 2011-04-21
NZ590923A (en) 2012-12-21
AU2009278279B2 (en) 2014-04-17
ECSP11010808A (es) 2011-03-31
BRPI0917099A2 (pt) 2016-02-16
WO2010015340A1 (en) 2010-02-11

Similar Documents

Publication Publication Date Title
UY32037A (es) Daa-piridina
MX2013012793A (es) Aminoacidos radiomarcados para imagen de diagnostico.
CL2012002189A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos.
CR20110466A (es) Anticuerpos biespecíficos anti-erbb-3/anti-c-met
BR112012032008A2 (pt) anticorpos s100a4 e usos terapêuticos do mesmo
MX348733B (es) Composiciones de radiorastreador de peptido.
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
NI201100082A (es) Compuestos de isoindolina para uso en el tratamiento de cáncer.
EP4374924A3 (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
MX346145B (es) Composición de sistema de suministro de arnsi in vivo basado en péptidos.
UY30595A1 (es) Métodos de marcacion con fluor radioactivo
BR112015015368A2 (pt) composições de absorventes de dejetos de animais revestidas debaixa densidade
WO2009052970A3 (en) Compounds for use in imaging, diagnosing, and/or treatment of diseases of the central nervous system or of tumors
BR112012022337A2 (pt) composição e respectivos método de preparação e uso de quantidade eficaz
BR112012021579A2 (pt) traçador de tomografia por emissão de pósitron, composto precursor, método para preparar o composto precursor, cassete, composição radiofarmacêutica, método de formação de imagem por tomografia por emissão de pósitron, e, método para diagnose de uma condição.
UY33274A (es) Proteínas de unión a basigina
BR112012019920A2 (pt) derivados de piridazina úteis como agonístas de canabinoide-2.
AR105791A2 (es) Método para el tratamiento de biomasa
BR112012027316A2 (pt) métodos para obter um traçador de tomografia por emissão de pósitron e para a preparação do composto, e, cassete
MX2012012479A (es) Metodos, composiciones y accesorios para proporcionar un tratamiento terapeutico.
MX2013006202A (es) Metodo de radioconjugacion.
PH12013501017A1 (en) Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system
ECSP099505A (es) Marcación radioactiva por fluoración de aziridinas
BR112013006498A2 (pt) composto
MX2013010781A (es) Compuestos para usarse en formacion de imagenes, diagnostico y/o tratamiento de enfermedades del sistema nervioso central.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20181112